
IFPx is developing a novel patient monitoring system aimed at transforming the management of chronic conditions, starting with heart failure. Their core innovation is the IFPx sensor, which directly measures interstitial fluid pressure, a key indicator of heart failure progression. This minimally invasive, implantable sensor provides a direct physiological metric alongside core data like heart rate, ECG, and afib detection. By integrating these multi-parameters and leveraging AI, the system offers timely alerts and predictions to clinicians, helping to prevent hospitalizations driven by fluid overload. IFPx's platform is positioned as a new standard of care, offering broad applications beyond heart failure, including kidney and liver failure management.

IFPx is developing a novel patient monitoring system aimed at transforming the management of chronic conditions, starting with heart failure. Their core innovation is the IFPx sensor, which directly measures interstitial fluid pressure, a key indicator of heart failure progression. This minimally invasive, implantable sensor provides a direct physiological metric alongside core data like heart rate, ECG, and afib detection. By integrating these multi-parameters and leveraging AI, the system offers timely alerts and predictions to clinicians, helping to prevent hospitalizations driven by fluid overload. IFPx's platform is positioned as a new standard of care, offering broad applications beyond heart failure, including kidney and liver failure management.
Product: IFPx System — subcutaneous implantable sensor that measures interstitial fluid pressure plus physiologic parameters
Clinical focus: Initial target: heart failure management to detect fluid overload and reduce hospitalizations
Technology: Direct chronic monitoring of interstitial fluid pressure (digitized pitting edema concept)
Affiliation: Portfolio company of NXT Biomedical; participated in MedTech Innovator 2023 Accelerator
Chronic disease monitoring, specifically heart failure management (fluid overload detection); potential broader use in kidney and liver failure management.
Medical devices / Digital health
“Portfolio company of NXT Biomedical; participated in MedTech Innovator 2023 Accelerator”